Form 8-K - Current report:
SEC Accession No. 0001213900-25-052141
Filing Date
2025-06-06
Accepted
2025-06-06 16:30:13
Documents
14
Period of Report
2025-06-06
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0244929-8k_nektar.htm   iXBRL 8-K 38457
2 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF THE COMPANY DATE ea024492901ex3-1_nektar.htm EX-3.1 7548
3 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF THE COMPANY DATE ea024492901ex3-2_nektar.htm EX-3.2 7602
  Complete submission text file 0001213900-25-052141.txt   223814

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nktr-20250606.xsd EX-101.SCH 3008
5 XBRL LABEL FILE nktr-20250606_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE nktr-20250606_pre.xml EX-101.PRE 22354
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0244929-8k_nektar_htm.xml XML 3686
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 251031150
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)